Trial report in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Eduardo GotuzzoInstituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.ORCID 0000-0003-1747-4352
Debra BenatorInfectious Diseases Section, Washington DC Veterans Affairs Medical Center, George Washington University, Washington, District of Columbia.ORCID 0000-0003-0866-4453
Robin M WarrenDivision of Molecular Biology and Human Genetics, Faculty of Medicine and Health Science, SAMRC Centre for Tuberculosis, Stellenbosch University, Cape Town, South Africa.
David SikesLaboratory Branch, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia.
Leonid LeccaSocios En Salud Sucursal Perú, Lima, Peru.
Neel R GandhiDepartments of Epidemiology, Global Health, and Medicine and Emory/Georgia Tuberculosis Research Advancement Center, Emory University, Atlanta, Georgia.ORCID 0000-0002-1665-299X
Elizabeth M StreicherDivision of Molecular Biology and Human Genetics, Faculty of Medicine and Health Science, SAMRC Centre for Tuberculosis, Stellenbosch University, Cape Town, South Africa.
Carole D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts; and.
C Robert HorsburghDepartments of Epidemiology, Biostatistics, Global Health, and Medicine, Boston University Schools of Public Health and Medicine, Boston, Massachusetts.ORCID 0000-0001-6838-7895
Funding
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Neel Rajnikant Gandhi, Jyothi Rengarajan · 2022 to 2026
$5.8M
Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB TreatmentU01AI100805 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HORSBURGH, CHARLES ROBERT · 2013 to 2016
$5.4M
The impact of alcohol consumption on TB treatment outcomesR01AI119037 · NIAID · BOSTON MEDICAL CENTER · PI JACOBSON, KAREN R · 2016 to 2020
$3.3M
Impact of Pregnancy on TuberculosisR01AI124217 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ELLNER, JERROLD J. · 2015 to 2018
$2.6M
Supplement to Methods to Estimate the Effect of Interventions on the Incidence and Transmission of TuberculosisR01GM122876 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WHITE, LAURA FORSBERG · 2017 to 2021
$1.9M
Mentorship in Patient-Oriented Research in Tuberculosis, HIV and Global HealthK24AI114444 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2014 to 2023
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial. · full record | OpenQuestion